Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanisms of resistance to rapamycins.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Dec 2001

Huang S, Houghton P J

Abstract excerpt

Rapamycins represent a novel family of anticancer agents, currently including rapamycin and its derivatives, CCI-779 and RAD001. Rapamycins inhibit the function of the mammalian target of rapamycin (mTOR), and potently suppress tumor cell growth by arresting cells in G1 phase or potentially inducing apoptosis of cells, in culture or in xenograft tumor models. However, recent data indicate that genetic mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics, Antineoplastic
Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phosphoric Monoester Hydrolases

Share to Proliferating Cell Nuclear Antigen

Share to Protein Kinases

Share to PTEN Phosphohydrolase

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 12030785
DOI: 10.1054/drup.2002.0227

Genes

ATM
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanisms of resistance to rapamycins.PMID 12030785Read ↗

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Semantic proximity Read ↗

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancerSemantic proximity Read ↗

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.Semantic proximity Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell LinesSemantic proximity Read ↗

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapySemantic proximity Read ↗

Impact of genetic alterations on mTOR-targeted cancer therapy.Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

An expanding role for mTOR in cancer.Semantic proximity Read ↗

Effects of rapamycin and AZD3463 combination on apoptosis, autophagy, and cell cycle for resistance control in breast cancer.Semantic proximity Read ↗

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.